Table 2 Side effects in patients receiving UC-MSCs infusions
Patient number | Clinical disease severity | Infusion round | EKG monitoring | POS monitoring (%) | Infusion associated events |
|---|---|---|---|---|---|
Patient T1 | Moderate | First infusion | Normal | 98 | Facial flushing occurred within 4 h after UC-MSCs transfusion and spontaneously relieved within 24 h |
Patient T4 | Moderate | Third infusion | Normal | 100 | Transient fever no more than 38 °C within 2 h after UC-MSCs transfusion and spontaneously relieved within 24 h |
Patient T6 | Severe | First infusion | Normal | 91–99 | Severe hypoxemia occurred within 12 h after UC-MSCs transfusion, believed to be associated with the progression of COVID-19, and recovered after HFNC (Humidified high-flow nasal cannula oxygen therapy) |
